SG Americas Securities’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $879K | Buy |
100,357
+62,567
| +166% | +$474K | ﹤0.01% | 1970 |
|
|
2026
Q1 | $290K | Sell |
37,790
-11,307
| -23% | -$77.4K | ﹤0.01% | 2475 |
|
|
2025
Q4 | $97K | Buy |
49,097
+18,791
| +62% | +$42.6K | ﹤0.01% | 3248 |
|
|
2025
Q3 | $75K | Buy |
+30,306
| New | +$78K | ﹤0.01% | 3136 |
|
|
2025
Q2 | – | Sell |
-42,188
| Closed | -$127K | – | 3236 |
|
|
2025
Q1 | $127K | Sell |
42,188
-18,152
| -30% | -$55K | ﹤0.01% | 2871 |
|
|
2024
Q4 | $154K | Buy |
60,340
+565
| +0.9% | +$2.35K | ﹤0.01% | 2389 |
|
|
2024
Q3 | $222K | Buy |
+59,775
| New | +$277K | ﹤0.01% | 2408 |
|
|
2024
Q1 | – | Sell |
-49,005
| Closed | -$246K | – | 3183 |
|
|
2023
Q4 | $246K | Buy |
49,005
+15,308
| +45% | +$48K | ﹤0.01% | 1978 |
|
|
2023
Q3 | $57K | Buy |
+33,697
| New | +$67.7K | ﹤0.01% | 2909 |
|
|
2023
Q2 | – | Sell |
-51,013
| Closed | -$93K | – | 2681 |
|
|
2023
Q1 | $93K | Buy |
51,013
+33,613
| +193% | +$105K | ﹤0.01% | 2937 |
|
|
2022
Q4 | $88K | Sell |
17,400
-80,262
| -82% | -$441K | ﹤0.01% | 2754 |
|
|
2022
Q3 | $485K | Buy |
97,662
+256
| +0.3% | +$1.17K | 0.01% | 1578 |
|
|
2022
Q2 | $362K | Buy |
97,406
+47,410
| +95% | +$190K | ﹤0.01% | 2236 |
|
|
2022
Q1 | $280K | Buy |
49,996
+23,617
| +90% | +$145K | ﹤0.01% | 2228 |
|
|
2021
Q4 | $160K | Sell |
26,379
-51,006
| -66% | -$383K | ﹤0.01% | 2782 |
|
|
2021
Q3 | $754K | Buy |
77,385
+45,125
| +140% | +$497K | ﹤0.01% | 2149 |
|
|
2021
Q2 | $461K | Buy |
32,260
+19,340
| +150% | +$319K | ﹤0.01% | 1976 |
|
|
2021
Q1 | $307K | Buy |
12,920
+2,789
| +28% | +$72.3K | ﹤0.01% | 2360 |
|
|
2020
Q4 | $135K | Buy |
+10,131
| New | +$97.5K | ﹤0.01% | 2878 |
|
|
2020
Q3 | – | Sell |
-15,635
| Closed | -$192K | – | 3046 |
|
|
2020
Q2 | $192K | Buy |
+15,635
| New | +$88.3K | ﹤0.01% | 2891 |
|
|
2019
Q1 | – | Sell |
-42,111
| Closed | -$49K | – | 3467 |
|
|
2018
Q4 | $49K | Buy |
+42,111
| New | +$96.3K | ﹤0.01% | 2827 |
|
|
2018
Q2 | – | Sell |
-21,812
| Closed | -$85K | – | 3421 |
|
|
2018
Q1 | $85K | Buy |
+21,812
| New | +$95.6K | ﹤0.01% | 3003 |
|
|
2017
Q4 | – | Sell |
-49,356
| Closed | -$270K | – | 3393 |
|
|
2017
Q3 | $270K | Buy |
49,356
+35,424
| +254% | +$218K | ﹤0.01% | 2340 |
|
|
2017
Q2 | $106K | Sell |
13,932
-13,104
| -48% | -$56.6K | ﹤0.01% | 2877 |
|
|
2017
Q1 | $96K | Sell |
27,036
-1,639
| -6% | -$8.1K | ﹤0.01% | 3005 |
|
|
2016
Q4 | $164K | Buy |
+28,675
| New | +$191K | ﹤0.01% | 2509 |
|
Other funds holding IBRX
SG Americas Securities's IBRX Position: Q2 2026 in Review
SG Americas Securities increased its ImmunityBio (IBRX) stake by 166% in Q2 2026, buying an estimated $474K and bringing the position to 100,357 shares worth $879K. The position accounts for ﹤0.01% of the portfolio, ranked #1970.
SG Americas Securities first reported a position in IBRX in Q4 2016 and has held it in 26 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.
- SG Americas Securities held 100,357 shares of ImmunityBio worth $879K as of Q2 2026.
- SG Americas Securities bought 62,567 ImmunityBio shares in Q2 2026, an estimated $474K.
- ImmunityBio made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1970 holding.
- SG Americas Securities first reported a position in ImmunityBio in Q4 2016 and has held it in 26 quarters since.
- 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.